← Scoopfeeds — Intelligent news, curated.
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
business

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

Yahoo Finance · Jun 30, 2026, 1:22 PM · Also reported by 2 other sources

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Why is Unicycive Therapeutics stock collapsing today? Investing.com Rapport Therapeutics stock hits all-time high at 42.36 USD

More in business

Decrypt
Sharplink Buys Ethereum for First Time in 2026—With ETH Down 68% From Peak
Decrypt
Dutch Prosecutors Seek to Bankrupt Crypto Platform Knaken After Funds Frozen
CNBC
GOP Rep. Tom Kean says depression diagnosis caused months-long absence from Congress
Investing.com
Why is Axon Enterprise stock surging today?
MarketWatch
Even Wall Street bulls are worried about a stock-market pullback after dazzling second quarter
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop